ライフサイエンスコーパス: loading dose

1 and 2 (patients in cohort 3 did not receive loading doses).

2 ssessed by VerifyNow 1, 2, and 4 hours after loading dose.

3 h platelet-rich plasma sampled 4 hours after loading dose.

4 her crushed or integral tablets of prasugrel loading dose.

5 t improvement only with a higher intravenous loading dose.

6 ce of initiating therapeutic regimens with a loading dose.

7 c adverse event rates compared with a 300-mg loading dose.

8 latelet inhibition than a 600-mg clopidogrel loading dose.

9 patients allocated AZD6140 received a 270-mg loading dose.

10 We have reported NR after a 300-mg loading dose.

11 f 1.0, 1.5, 2.0, or 2.5 mg/kg weekly with no loading dose.

12 or 4 (n=10) mg/m2/day for 14 days without a loading dose.

13 received sirolimus, 5 mg daily after a 15-mg loading dose.

14 mg or 2.0 mg monthly or PRN after 3 monthly loading doses.

15 ed monthly or on a PRN basis after 3 monthly loading doses.

16 monthly or pro re nata (PRN) after 3 monthly loading doses.

17 us administration of saline or dipyridamole (loading dose, 0.142 mg/kg per min for 5 minutes followed

18 hin 8 h of injury to either tranexamic acid (loading dose 1 g over 10 min followed by infusion of 1 g

19 hin 8 h of injury to either tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over 8

20 ials have shown leflunomide (LEF; 20 mg/day, loading dose 100 mg x 3 days) to be effective and safe f

21 cycline (50 mg intravenously every 12 hours; loading dose 100 mg).

22 After a loading dose (100 microg/kg), morphine infusions (23-26

23 ery 4 weeks during the treatment phase, with loading doses (120 mg subcutaneously) administered on st

24 The first four patients received a loading dose (15 mg/m2) of oral sirolimus on day 1 follo

25 Telet inhibition and patient Outcomes) trial loading dose (180 mg) with a high loading dose (600 mg)

26 dose (200 mg/kg) then 100 mg/kg TID; or (3) loading dose (200 mg/kg) followed by continuous infusion

27 ses: (1) 100 mg/kg IV 3 times/day (TID); (2) loading dose (200 mg/kg) then 100 mg/kg TID; or (3) load

28 t on a PPI at 6 h after a 600 mg clopidogrel loading dose (23.2+/-19.5% vs 35.2+/-20.9%, p=0.02), whe

29 T474 tumors were given trastuzumab (50 mg/kg loading dose, 25 mg/kg maintenance dose, administered in

30 t administered subcutaneously once per week (loading dose 320 mg followed by 160 mg weekly) or placeb

31 apatinib (1500 mg), intravenous trastuzumab (loading dose 4 mg/kg [DOSAGE ERROR CORRECTED], subsequen

32 All patients received 3 loading doses 4 weeks apart and thereafter were assessed

33 (40,000 kallikrein inhibitor units [KIU]/kg loading dose, 40,000 KIU/kg pump prime, and 10,000 KIU/k

34 zumab emtansine 3.6 mg/kg; pertuzumab 840 mg loading dose, 420 mg maintenance doses) or docetaxel, ca

35 f-administered injections of growth hormone (loading dose, 5 mg per day subcutaneously for one week,

36 ime curve 6 mg/mL x min; trastuzumab 8 mg/kg loading dose, 6 mg/kg maintenance doses) plus pertuzumab

37 mes) trial loading dose (180 mg) with a high loading dose (600 mg) of clopidogrel.

38 ed to groups given JNJ-6379 at 25 mg (100 mg loading dose), 75 mg, 150 mg, or 250 mg or placebo daily

39 or standard-dose clopidogrel (no additional loading dose, 75 mg daily) for 6 months.

40 , to receive either subcutaneous adalimumab (loading dose 80 mg; biweekly dose 40 mg) or placebo, wit

41 randomly assigned to receive an intravenous loading dose (800 mg) plus 5 maintenance doses (200 mg e

42 All patients received ticagrelor 180-mg loading dose administered as crushed tablets at the time

43 galcanezumab 120 mg per month (with a 240 mg loading dose administered as two 120 mg injections) for

44 (arm A) or concurrent cetuximab 400 mg/m(2) loading dose and 250 mg/m(2) per week during RT (arm B).

45 0 mg thereafter; plus trastuzumab at 8 mg/kg loading dose and 6 mg/kg thereafter; and docetaxel at 75

46 y intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clop

47 y maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6

48 between eras included elimination of the SRL loading dose and a reduction in TAC target trough concen

49 Both the loading dose and maintenance dose of prasugrel were supe

50 Results under loading dose and maintenance therapy regimens were nearl

51 es suggest that longer intervals between the loading dose and PCI may reduce events.

52 ), with the addition of trastuzumab (4 mg/kg loading dose and then 2 mg/kg weekly or 8 mg/kg loading

53 spital to receive either rosuvastatin (40 mg loading dose and then 20 mg daily until the earliest of

54 e randomly assigned to cetuximab 400 mg/m(2) loading dose and then 250 mg/m(2) once per week with or

55 ding dose and then 2 mg/kg weekly or 8 mg/kg loading dose and then 6 mg/kg every 3 weeks).

56 were treated with cetuximab 400 mg/m(2) as a loading dose and then weekly cetuximab 250 mg/m(2) with

57 were observed among patients who received a loading dose and those who had a shorter duration of nAM

58 atio using computer randomisation to receive loading doses and then 30 days of intensive antiplatelet

59 Both groups received 3 monthly loading doses and were then treated every 8 weeks (q8) w

60 received pre-treatment with prasugrel (30-mg loading dose), and 1,376 received placebo.

61 mics of a 300-mg versus a 600-mg clopidogrel loading dose, and the comparative effect of eptifibatide

62 /kg in 100 mL of 0.9% saline over 4 hrs as a loading dose, and then a maintenance infusion of 50 mg/k

63 5 mg PRN group was 9.9 weeks after 3 monthly loading doses, and 93% of these patients did not require

64 ys 1 and 8 and weekly thereafter (plus an IV loading dose [ approximately 10 mg/kg] on day 1) or IV a

65 istered intravenously every 3 weeks (8 mg/kg loading dose at first cycle, and 6 mg/kg thereafter) for

66 ed trial compared cangrelor with clopidogrel loading dose at the time of PCI.

67 ofatumumab (20 mg every 4 weeks after 20-mg loading doses at days 1, 7, and 14) or oral teriflunomid

68 Aspirin loading dose before elective PCI improves myocardial rep

69 choice of administration of the clopidogrel loading dose before or after the start of PCI had an imp

70 e the optimal timing of a 300-mg clopidogrel loading dose before percutaneous coronary intervention (

71 domly assigned to receive prasugrel (a 30-mg loading dose) before the angiography (pretreatment group

72 umab (8.1 [2.3-28.7]; p=0.0012), and 160 mg (loading dose) bimekizumab (9.7 [2.7-34.3]; p=0.0004) gro

73 her with cetuximab (250 mg/m(2) weekly after loading dose; cetuximab group) or without (control group

74 id and greater platelet inhibition than high-loading-dose clopidogrel; this was sustained during the

75 Optimal clopidogrel loading dose during carotid stenting has not been invest

76 al aflibercept was administered as 3 initial loading doses every 4 weeks (week 0, week 4, and week 8)

77 eatment consisted of trastuzumab (T) 4 mg/kg loading dose followed by 2 mg/kg on days 1, 8, and 15; p

78 Trastuzumab was administered as a 4 mg/kg loading dose followed by 2 mg/kg weekly for 12 weeks.

79 ast cancer patients (ie, 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly).

80 (1500 mg), intravenous trastuzumab (4 mg/kg loading dose followed by 2 mg/kg), or lapatinib (1000 mg

81 weeks plus concurrent cetuximab (400 mg/m(2) loading dose followed by 250 mg/m(2) weekly) for four cy

82 re enrolled on 3 cohorts (cohort 1, 30 mg/m2 loading dose followed by 30 mg/m2 4-hour infusion; cohor

83 Subcutaneous dupilumab (a 600 mg loading dose followed by 300 mg weekly; n = 30) or place

84 initiated a phase 1 study using a 30-minute loading dose followed by 4 hours of infusion administere

85 d to receive adalimumab, 80-mg, subcutaneous loading dose followed by 40 mg every other week or place

86 30 mg/m2 4-hour infusion; cohort 2, 40 mg/m2 loading dose followed by 40 mg/m2 4-hour infusion; and c

87 mg/kg every 3 weeks) and pertuzumab (840 mg loading dose followed by 420 mg every 3 weeks) concurren

88 receive either placebo or pertuzumab (840-mg loading dose followed by 420 mg every 3 weeks).

89 h vehicle, 5 mg/kg remdesivir, or a 10-mg/kg loading dose followed by 5 mg/kg remdesivir.

90 n 200 mg QWk (400/200 mg), or CAS 70 mg as a loading dose followed by 50 mg daily for <= 4 weeks.

91 tion ACS to 1 of 3 doses of atopaxar (400-mg loading dose followed by 50, 100, or 200 mg daily) or ma

92 cetaxel 100 mg/m(2) plus trastuzumab 8 mg/kg loading dose followed by 6 mg/kg either with bevacizumab

93 antibody treatment with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) and pert

94 assigned oral losmapimod (7.5 mg or 15.0 mg loading dose followed by 7.5 mg twice daily) or matching

95 Administration of aspirin, 325-mg loading dose followed by 81 mg/d (n = 195) or placebo (n

96 olistin (9 million international units [MIU] loading dose followed by 9 MIU daily for normal renal fu

97 -one ratio to ticagrelor and placebo (180 mg loading dose followed by 90 mg twice a day), or to clopi

98 30-day regimen of either ticagrelor (180-mg loading dose followed by 90 mg twice daily) plus aspirin

99 s were randomly assigned to receive a 30-min loading dose followed by 96-hr infusions of placebo, TAK

100 Trastuzumab was given at 4 mg/kg loading dose followed by a 2 mg/kg dose once per week du

101 dose for treatments 1 to 4, then a 30 mg/m2 loading dose followed by a 50 mg/m2 4-hour infusion).

102 on-pump inhibitor (PPI) therapy (intravenous loading dose followed by continuous infusion) for 3 days

103 mg/m(2) once per week or CTX 400 mg/m(2) as loading dose followed by CTX 250 mg/m(2) once per week c

104 omly assigned to receive clopidogrel (300-mg loading dose followed by daily dose of 75 mg; n = 441) o

105 o receive the following: a 40 mg/kg IV VRC01 loading dose followed by five 20 mg/kg IV VRC01 doses ev

106 erapy) or intravenous cetuximab (400 mg/m(2) loading dose followed by seven weekly infusions of 250 m

107 to receive cetuximab 400 mg/m(2) intravenous loading dose followed by weekly maintenance of 250 mg/m(

108 l regimens tended to follow a large initial 'loading' dose followed by doses of incremental reduction

109 gned in a 2:1:1 ratio to oral tolevamer 9 g (loading dose) followed by 3 g every 8 hours for 14 days,

110 ibizumab with TRP, or 3 monthly ranibizumab (loading doses) followed by as-needed (PRN) injections an

111 bitor units [KIU] in pump prime, 2x10(6) KIU loading dose, followed by 0.5x10(6) KIU/h [n=13]).

112 irst-line treatment with trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly, or a higher 8

113 lowed by 2 mg/kg weekly, or a higher 8 mg/kg loading dose, followed by 4 mg/kg weekly.

114 2 if tolerated; group A), pertuzumab (840 mg loading dose, followed by 420 mg every 3 weeks) and tras

115 m, to receive intravenous pertuzumab (840 mg loading dose, followed by 420 mg maintenance doses) plus

116 r neoadjuvant cycles of trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) plus do

117 doses) plus intravenous trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg maintenance doses) or

118 assigned them to receive clopidogrel (300-mg loading dose, followed by 75 mg once daily) or placebo.

119 o receive CytoFab, infused as a 250-units/kg loading dose, followed by nine doses of 50 units/kg ever

120 ungin acetate given intravenously as a 70-mg loading dose, followed up by 50 mg daily along with stan

121 To extend the anti-VEGF loading dose from 3 to 6 injections necessitates investi

122 ared with the 300-mg (n = 1,153) clopidogrel loading dose group had significantly lower 30-day unadju

123 ]; P=0.02) in the 100-mg compared with 60-mg loading dose group.

124 om day 29 through 12 months, patients in the loading-dose group received clopidogrel, 75 mg/d, and th

125 ) once every 3 weeks plus pertuzumab (840 mg loading dose --> 420 mg) once every 3 weeks, all given i

126 m(2) once per week plus trastuzumab (8 mg/kg loading dose --> 6 mg/kg) once every 3 weeks plus pertuz

127 r prasugrel (n = 95) or ticagrelor (n = 205) loading dose had platelet reactivity assessed by VerifyN

128 (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plu

129 g From Clopidogrel Loading Dose To Prasugrel Loading Dose In Acute Coronary Syndrome Patients study:

130 Extending the loading dose in nonresponder patients would cost euro 21

131 thereafter) for 18 doses or weekly (4 mg/kg loading dose in the first week, and 2 mg/kg thereafter)

132 Despite the inclusion of a loading dose in the Platelet Inhibition and Patient Outc

133 weekly maintenance dose; part C, to study a loading dose in week 2; and a tumor biopsy cohort.

134 ent study was to assess whether a ticagrelor loading dose is associated with a further platelet inhib

135 52) who were treated with a prasugrel 60-mg loading dose (LD) either as whole or crushed tablets.

136 5-day run-in phase with a ticagrelor 180-mg loading dose (LD) followed by a ticagrelor 90-mg twice-d

137 PD effects of ticagrelor versus clopidogrel loading dose (LD) in the peri-procedural period among tr

138 To evaluate whether chewing a loading dose (LD) of ticagrelor, 180 mg, vs traditional

139 pen-label randomly assigned to a fulvestrant loading dose (LD) regimen followed by monthly injection

140 Adding a prasugrel loading dose (LD) to a clopidogrel LD could be desirable

141 de effective platelet inhibition 2 h after a loading dose (LD).

142 to 1 of the following 3 treatments: placebo loading dose (LD)/clopidogrel 75 mg maintenance dose (MD

143 4, and 8, with placebo at week 2; or 420 mg loading dose [LD] at week 0 followed by 300 mg at weeks

144 o receive either clopidogrel (300- to 600-mg loading dose [LD], 75 mg/day) or ticagrelor (180-mg LD,

145 andomly assigned to receive prasugrel (60 mg loading dose [LD]/10 mg maintenance dose once daily) or

146 estored using concentrated platelets after a loading dose/maintenance therapy in a time-dependent man

147 of aflibercept without the initial 3 monthly loading doses may be a good alternative in a select grou

148 nd leronlimab dose, suggesting that a higher loading dose might be more effective.

149 mly assigned to receive a 300-mg clopidogrel loading dose (n = 1053) or placebo (n = 1063) 3 to 24 ho

150 (n = 249) or as needed (PRN) after 3 monthly loading doses (n = 251).

151 ntration may be achieved with an intravenous loading dose of 0.45 mg/kg followed by a continuous infu

152 LEF was initiated with a loading dose of 100 mg daily for 3 days in 61% of patien

153 Cetuximab was delivered as a loading dose of 100 to 500 mg/m(2), followed by weekly i

154 viduals in the pexidartinib group received a loading dose of 1000 mg pexidartinib per day orally (400

155 eive levosimendan, 0.1 microg/kg/min after a loading dose of 12 microg/kg (n=15), or placebo (n=15).

156 /mL (300 microM) was calculated to require a loading dose of 1200-1400 mg over a 7-day period.

157 Levosimendan was administered in a loading dose of 20 microg.kg over 10 mins followed by a

158 Patients were followed for 1 year, with a loading dose of 3 monthly intravitreal injections, follo

159 All patients received an initial loading dose of 300 mg of rilonacept by subcutaneous inj

160 dogrel (75 mg/d for long-term treatment or a loading dose of 300 mg) before the following tests.

161 Hypothermia group received a loading dose of 4 degrees C cold saline and were cooled

162 voriconazole vs oral placebo; a voriconazole loading dose of 400 mg was administered twice daily for

163 to receive either intravenous cetuximab at a loading dose of 400 mg/m(2) 5-7 days before radiotherapy

164 very 2 weeks with regimen one and three or a loading dose of 400 mg/m(2) followed by a weekly infusio

165 very 2 weeks with regimen one and three or a loading dose of 400 mg/m(2) followed by a weekly infusio

166 ous infusion at 250 mg/m(2) after an initial loading dose of 400 mg/m(2) in week 1.

167 mg/m(2)), or cetuximab (250 mg/m(2) after a loading dose of 400 mg/m(2)) until disease progression,

168 yrimidines, were treated with cetuximab at a loading dose of 400 mg/m2 followed by 250 mg/m2 weekly.

169 50 mg/m2 days 1, 8, and 15 (after an initial loading dose of 400 mg/m2), termed TPE, repeated every 2

170 commended dose for phase II/III studies is a loading dose of 400 to 500 mg/m(2) and a maintenance wee

171 After a loading dose of 5 mg, patients received a daily dose of

172 Patients were treated with an oral sirolimus-loading dose of 6 mg after coronary angioplasty, followe

173 Twenty-four healthy subjects received a loading dose of 600 mg clopidogrel together with placebo

174 hours after PCI, was not superior to an oral loading dose of 600 mg of clopidogrel, administered 30 m

175 us and infusion of cangrelor or to receive a loading dose of 600 mg or 300 mg of clopidogrel.

176 Amiodarone (200 mg/d after loading dose of 600 mg/d for 10 days) was used as a cali

177 r one of three ALS-008176 dosing regimens: 1 loading dose of 750 mg followed by 9 maintenance doses o

178 y 9 maintenance doses of 500 mg (group 1), 1 loading dose of 750 mg followed by 9 maintenance doses o

179 ys) or trastuzumab-capecitabine (trastuzumab loading dose of 8 mg/kg followed by an infusion of 6 mg/

180 zumab delivered every 3 weeks intravenously (loading dose of 8 mg/kg followed by maintenance doses of

181 gned in a 1:1 ratio to receive adalimumab (a loading dose of 80 mg followed by a dose of 40 mg every

182 Patients received a loading dose of 840 mg pertuzumab (cycle 1) followed by

183 ients in the first cohort treated at 420 mg (loading dose of 840 mg) allowed termination of additiona

184 to receive either pertuzumab or placebo at a loading dose of 840 mg, and 420 mg thereafter; plus tras

185 The CMS dosing schedule was based on a loading dose of 9 MU and a 9-MU twice-daily fractioned m

186 enous LA 450 mg plus oral prasugrel 60 mg or loading dose of aspirin 300 mg plus prasugrel 60 mg oral

187 r bare metal stent), CYP2C19 genetic status, loading dose of aspirin, dose of clopidogrel before rand

188 A single high loading dose of atorvastatin administered within 24 hour

189 ore MI induction: (1) placebo-control; (2) a loading dose of clopidogrel (600 mg); (3) a loading dose

190 A loading dose of clopidogrel before a PCI has become rela

191 rmediate risk patients treated with a 600-mg loading dose of clopidogrel before PCI, incremental clin

192 A 600-mg loading dose of clopidogrel compared with 300 mg provide

193 Our aim was to determine whether a 600-mg loading dose of clopidogrel compared with 300 mg results

194 A loading dose of clopidogrel given at least 3 hours befor

195 When a 300-mg loading dose of clopidogrel is used, little benefit is o

196 temporary anticoagulation regimens, a 600-mg loading dose of clopidogrel may safely reduce 30-day isc

197 nset of an antiplatelet effect seen with the loading dose of clopidogrel, which was used in most of t

198 n the duration of pretreatment with a 600-mg loading dose of clopidogrel.

199 Four hours after she received the loading dose of cyproheptadine, she was alert and orient

200 1:1 randomization to receive either a single loading dose of girentuximab, 50 mg (week 1), followed b

201 A 10-min loading dose of intravenous ghrelin/placebo (3 mcg kg(-1

202 Subjects were randomly assigned to receive a loading dose of intravenous LA 450 mg plus oral prasugre

203 ose of intravenous pembrolizumab and 8 mg/kg loading dose of intravenous trastuzumab.

204 Loading dose of LA achieves an earlier platelet inhibiti

205 All patients received a loading dose of morphine 30 minutes before the end of su

206 fective were treated transplacentally with a loading dose of oral amiodarone for 2 to 7 days, followe

207 as seen with and without a PPI after a 60 mg loading dose of prasugrel (69.6+/-13.5% vs 76.7+/-12.4%,

208 on followed by 60 mg of prasugrel), or 60-mg loading dose of prasugrel (n=42).

209 e in the ambulance, before transfer, a 60-mg loading dose of prasugrel either as crushed or integral

210 r the first 2 hours after the standard 60 mg loading dose of prasugrel has been described.

211 vention, a higher (100 mg) than the standard loading dose of prasugrel results in greater and more co

212 those who received placebo received a 60-mg loading dose of prasugrel.

213 The single oral loading dose of propafenone appears to be highly effecti

214 whereas 83% of animals receiving a 10-mg/kg loading dose of remdesivir survived, as did 50% of anima

215 k baseline, patients received a subcutaneous loading dose of rilonacept 320 mg followed by weekly sub

216 nary angiography with planned PCI to an oral loading dose of SCH 530348 (10 mg, 20 mg, or 40 mg) or m

217 ns of surgical technique, and avoidance of a loading dose of sirolimus.

218 ly assigned in a 1 to 1 fashion to receive a loading dose of study drug (prasugrel 60 mg or clopidogr

219 A loading dose of study drug was administered on cardiopul

220 sought to assess platelet inhibition after a loading dose of the currently recommended antiplatelet a

221 loading dose of clopidogrel (600 mg); (3) a loading dose of ticagrelor (180 mg); or (4) a loading do

222 t-elevation myocardial infarction received a loading dose of ticagrelor and were randomized to mainte

223 oading dose of ticagrelor (180 mg); or (4) a loading dose of ticagrelor followed by an adenosine A1/A

224 A loading dose of trastuzumab 4 mg/kg was administered 1 d

225 s randomly assigned to arm A received a 4-mg loading dose of trastuzumab followed by 2 mg weekly; in

226 eir 20-mg test dose or after their 400 mg/m2 loading dose of unlabeled C225 (patients 1/3/5 and 2/4/6

227 ents received PRM-151 in 28-week cycles with loading doses of 10 mg/kg by 60 min intravenous infusion

228 ion cohort this regimen was preceded by four loading doses of 3 mg/kg once weekly.

229 all US patients (99.1%) received clopidogrel loading doses of 600 mg, whereas 40.5% of non-US patient

230 f custirsen 640 mg intravenously after three loading doses of 640 mg.

231 ents with treatment naive DMO treated with 3 loading doses of aflibercept were included in the study.

232 y of persistent disease activity following 3 loading doses of anti- vascular endothelial growth facto

233 ercutaneous coronary intervention, receiving loading doses of clopidogrel (600 mg, n=13 or 900 mg, n=

234 ized to the study group received four to six loading doses of ivID, 100 mg each, over a 2-wk period t

235 Subjects were randomized 2:1 to 3 loading doses of ranibizumab then retreatment every 4 we

236 After 2 initial monthly loading doses of ranibizumab, subsequent ranibizumab was

237 electrographic seizures not responding to a loading-dose of phenobarbital from eight neonatal intens

238 located patients (1:1) to ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for

239 weekly trastuzumab intravenously at 4 mg/kg loading dose on day 1 with subsequent weekly doses of 2

240 estrant 500 mg (day 1) every 28 days (plus a loading dose on day 15 of cycle 1) with either capivaser

241 ilable on the comparative effect of a 600-mg loading dose on the incidence of NR and high post-PA.

242 of subcutaneous denosumab every 4 weeks with loading doses on days 8 and 15 of the first cycle; those

243 /m(2), plus intravenous trastuzumab 4 mg/kg (loading dose) on day 1 and 2 mg/kg on days 1, 8, and 15

244 rasugrel, administered as chewed or integral loading dose, on IPA in patients undergoing primary perc

245 (2) and trastuzumab 2 mg/kg (after a 4 mg/kg loading dose) once per week for 12 weeks, while those ra

246 ), or to clopidogrel and placebo (300-600 mg loading dose or continuation with maintenance dose follo

247 eous adalimumab (40 mg every 2 weeks after a loading dose) or low-dosage oral methotrexate sodium (7.

248 ab, 160 mg bimekizumab with a one-off 320 mg loading dose, or 320 mg bimekizumab, which were administ

249 g schemes; greatest increase occurred with a loading dose (P < .001).

250 d point was platelet reactivity 2 hours post loading dose (P2Y12 reactivity units [PRU] measured by t

251 After the loading doses, patients in either arm who showed signs o

252 The primary end point of the loading-dose phase (prasugrel 60 mg versus clopidogrel 6

253 to six cycles of either trastuzumab 4 mg/kg loading dose plus 2 mg/kg weekly thereafter with paclita

254 2 every 3 weeks (TP), or trastuzumab 4 mg/kg loading dose plus 2 mg/kg weekly thereafter with paclita

255 90 mg, AZD6140 180 mg, or clopidogrel 300-mg loading dose plus 75 mg once daily for up to 12 weeks.

256 tandard clopidogrel therapy (300-600 mg oral loading dose plus 75 mg oral maintenance dose) in 56 pat

257 trastuzumab (2 mg/kg per week after 4 mg/kg loading dose) plus vinorelbine.

258 including higher clopidogrel maintenance and loading doses, prasugrel, and ticagrelor, clinicians can

259 rge clot embolization in order to achieve a "loading dose" pretreatment with the drug.

260 fit for beginning therapy with a clopidogrel loading dose prior to PCI, the practical application of

261 s infusion of lorazepam, preceded by a bolus loading dose, produces a relatively constant sedative ef

262 A 600-mg clopidogrel loading dose reduces the incidence of NR and high post-P

263 rol (standard dosing) group received a 3-day loading-dose regimen.

264 ent, the optimal timing of P2Y(12) inhibitor loading dose remains debated.

265 At hour 2, prasugrel 100 mg over 60 mg loading dose significantly reduced high platelet reactiv

266 Seventy-seven patients received an SIR loading dose (SIR-LD) immediately posttransplantation, a

267 splantation, and 41 patients did not (SIR no loading dose [SIR-NLD]).

268 .3%) and 600-mg (10.4% vs. 7.3%) clopidogrel loading dose subgroups (p(interaction) = 0.41).

269 bevacizumab injections every 12 weeks after loading doses supplemented with as-needed top-up treatme

270 d less well functionally and anatomically to loading dose than eyes with baseline CST of 400 um or mo

271 us) in combination with trastuzumab (4 mg/kg loading dose then 2 mg/kg weekly) to determine the OTR.

272 h TIA or minor stroke to clopidogrel (300 mg loading dose then 75 mg daily; 198 patients) or placebo

273 Trastuzumab (4 mg/kg loading dose, then 2 mg/kg weekly during paclitaxel then

274 d to commence subcutaneous dupilumab (600 mg loading dose, then 300 mg once weekly for 15 weeks [n =

275 Patients received pertuzumab (840 mg loading dose, then 420 mg every 3 weeks, intravenously)

276 with 3.6 mg/kg T-DM1 plus pertuzumab (840-mg loading dose, then 420 mg subsequently) once every 3 wee

277 eks, intravenously) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, intravenously)

278 T12PR24 group, receiving telaprevir (1125-mg loading dose, then 750 mg every 8 hours) for 12 weeks an

279 before study entry, plus cetuximab 400 mg/m2 loading dose, then weekly cetuximab 250 mg/m2, plus beva

280 ceived dual antiplatelet therapy as a single loading dose (ticagrelor 180 mg plus aspirin 325 mg) and

281 grel 600 mg in Transferring From Clopidogrel Loading Dose To Prasugrel Loading Dose In Acute Coronary

282 The loading dose treatment achieved resolution of all fluid

283 tly increased in VOE subjects after arginine-loading dose treatment.

284 d to receive clopidogrel were given a 300-mg loading dose unless they had already been treated with c

285 ly on days 1, 8, and 15, plus three previous loading doses) until disease progression, unacceptable t

286 s greatest in the two groups that received a loading dose--viral clearance was accelerated (P</=0.05)

287 P2Y12 reactivity units 2 hours after the loading dose was 187 (153-221) and 133 (102-165) in pati

288 multivariable analysis, a 600-mg clopidogrel loading dose was an independent predictor of lower rates

289 Visual acuity after the third loading dose was associated significantly with the outco

290 In the clopidogrel-only group (n=5438), a loading dose was given before (early load [EL]) or after

291 A loading dose was initiated by paramedics before the pati

292 Least-squares mean PRU at 2 hours post loading dose was lower with ticagrelor (27.6) versus clo

293 likely to be discontinued if a 3-day 100-mg loading dose was prescribed, patients were younger than

294 ndomization heparin and a 600-mg clopidogrel loading dose were independent predictors of reduced acut

295 Loading doses were administered immediately after the pr

296 f 16 mg and 160 mg (with or without a 320 mg loading dose) were associated with significant improveme

297 raphic effects were maximal 0.5 hr after the loading dose, were maintained essentially constant durin

298 roups--clinical presentation and clopidogrel loading dose--were analyzed.

299 ndomization was stratified by thienopyridine loading dose, which was determined before random assignm

300 ersistent disease activity after the initial loading dose, with poorer BCVA compared to those without